Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



FDA Approves Novartis Leukemia Drug to Treat Youth

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Novartis (NYSE: NVS  ) has received approval from the Food and Drug Administration for the treatment of children with its leukemia drug Gleevec, the regulator announced today. The drug, a form of the company's existing medication Glivec, may now be prescribed to children diagnosed with a type of lymphoblastic leukemia.

The affliction occurs when a genetic abnormality causes certain proteins stimulating bone marrow to produce an excessive amount of immature white blood cells. This is the most common type of cancer in children, striking nearly 3,000 every year. It worsens rapidly if left untreated.

Gleevec was first approved in 2001 to treat certain forms of the disease; approval has since been expanded to cover other types.

Read/Post Comments (0) | Recommend This Article (0)

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2216772, ~/Articles/ArticleHandler.aspx, 9/26/2016 1:27:34 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,123.04 -138.41 -0.76%
S&P 500 2,149.55 -15.14 -0.70%
NASD 5,262.37 -43.37 -0.82%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/26/2016 1:11 PM
NVS $80.74 Down -0.74 -0.91%
Novartis CAPS Rating: ****